Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M159,821Revenue $M11,202Net Margin (%)42.8Z-Score8.6
Enterprise Value $M163,081EPS $1.8Operating Margin %56.2F-Score7
P/E(ttm))39.1Cash Flow Per Share $4.3Pre-tax Margin (%)54.2Higher ROA y-yY
Price/Book11.910-y EBITDA Growth Rate %0Quick Ratio1.7Cash flow > EarningsN
Price/Sales13.25-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow17.4y-y EBITDA Growth Rate %47.7ROA % (ttm)29.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)58.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,536ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 106.4237%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 106.4237%New holding, 466853 sh.466,853
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 106.4237%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 106.4237%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 106.4237%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 106.4237%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 106.4237%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 106.4236%Add 7.91%345,320
GILDRay Dalio 2014-03-31 Add0.12%$68.55 - $83.95
($78.44)
$ 106.4236%Add 541.42%247,721
GILDGeorge Soros 2014-03-31 Buy 0.04%$68.55 - $83.95
($78.44)
$ 106.4236%New holding, 50000 sh.50,000
GILDJohn Burbank 2014-03-31 Buy 0.01%$68.55 - $83.95
($78.44)
$ 106.4236%New holding, 3619 sh.3,619
GILDMario Gabelli 2014-03-31 Add$68.55 - $83.95
($78.44)
$ 106.4236%Add 31.65%44,240
GILDDaniel Loeb 2014-03-31 Sold Out -1.9%$68.55 - $83.95
($78.44)
$ 106.4236%Sold Out0
GILDJohn Griffin 2014-03-31 Sold Out -0.48%$68.55 - $83.95
($78.44)
$ 106.4236%Sold Out0
GILDVanguard Health Care Fund 2014-03-31 Reduce-0.46%$68.55 - $83.95
($78.28)
$ 106.4236%Reduce -41.41%2,713,300
GILDJulian Robertson 2013-12-31 Add1.52%$58.9 - $75.2
($69.65)
$ 106.4253%Add 25.84%320,001
GILDDaniel Loeb 2013-12-31 Add1.27%$58.9 - $75.2
($69.65)
$ 106.4253%Add 200%1,500,000
GILDRay Dalio 2013-12-31 Buy 0.02%$58.9 - $75.2
($69.65)
$ 106.4253%New holding, 38621 sh.38,621
GILDJohn Griffin 2013-12-31 Reduce-1.02%$58.9 - $75.2
($69.65)
$ 106.4253%Reduce -68.21%620,000
GILDJohn Hussman 2013-12-31 Sold Out -0.86%$58.9 - $75.2
($69.65)
$ 106.4253%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD Joel Greenblatt 2014-06-30466,8530.030.48New Buy
GILD Ray Dalio 2014-06-30349,8210.020.22+41.22%
GILD Julian Robertson 2014-06-30443,9110.0313.4+28.55%
GILD Mario Gabelli 2014-06-3049,17000.02+11.14%
GILD John Burbank 2014-06-303,77400.01+4.28%
GILD Jean-Marie Eveillard 2014-06-3040000
GILD Ronald Muhlenkamp 2014-06-30144,7150.012.1-24.63%
GILD Mariko Gordon 2014-06-3011,65400.04-35.57%
GILD Vanguard Health Care Fund 2014-06-301,633,7000.110.36-39.79%
GILD George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Carter Paul RutherfordEVP Commercial Ops 2014-09-26Sell2,000$107.47-0.3view
Cogan John FrancisDirector 2014-09-22Sell5,000$106.60.52view
MILLIGAN JOHN FPresident and COO 2014-09-08Sell146,895$105.991.09view
Alton Gregg HEVP, Corp & Med Affairs 2014-09-02Sell33,000$108.58-1.32view
MARTIN JOHN CChairman and CEO 2014-09-02Sell140,625$108.64-1.37view
Whitley Richard JamesDirector 2014-09-02Sell5,000$108.1-0.88view
Carter Paul RutherfordEVP Commercial Ops 2014-08-26Sell10,000$106.160.93view
Washington Robin LEVP, CFO 2014-08-25Sell4,304$105.871.21view
Cogan John FrancisDirector 2014-08-21Sell5,000$101.095.99view
Washington Robin LEVP, CFO 2014-08-14Sell33,556$95.5612.13view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    There's More to Gilead Sciences than a Successful Drug Sep 26 2014 
    A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
    Gilead Sciences: Up Over 1,100% And Still Cheap Sep 09 2014 
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Everything's Going Right for Gilead Sciences Aug 26 2014 
    New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV Aug 18 2014 
    Julian Robertson Buys Tableau Software, Facebook, Netflix, Sells Ulta Salon, EBay, EQT Aug 14 2014 
    Creating Cures And Dividends Where None Existed Before With Gilead Sciences Jul 26 2014 
    Analyzing Why Gilead Sciences is Still a Great Buy Jul 24 2014 
    Why AbbVie Looks Like a Sell Jul 18 2014 


    More From Other Websites
    Most active Nasdaq-traded stocks Sep 30 2014
    Johnson & Johnson Bets $1.75 Billion On Alios Buy Sep 30 2014
    What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences Sep 30 2014
    Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% Sep 30 2014
    France uses tax to put pressure on hepatitis C drug prices Sep 30 2014
    The Zacks Analyst Blog Highlights: Penn National Gaming, Caesars Entertainment, Wynn Resorts, MGM... Sep 30 2014
    Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% Sep 30 2014
    Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session Sep 30 2014
    Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session Sep 30 2014
    Gilead's HCV Combo Drug Harvoni Secures CHMP Backing Sep 29 2014
    Gilead Sciences, Inc. Consolidating Gains? Sep 29 2014
    Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014
    Many IBD 50 Stocks Testing Key Support Level Sep 26 2014
    Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Sep 26 2014
    Can Gilead Sciences Be A Do-Gooder And Still Do Well? Sep 26 2014
    Gilead’s Hepatitis C Combination Wins EU Agency Backing Sep 26 2014
    Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Sep 26 2014
    Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session Sep 26 2014
    European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the... Sep 26 2014
    Gilead, Celgene Key Holdings Of Top Health Care Fund Sep 25 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK